公开(公告)号：US20190022108A1

公开(公告)日：2019-01-24

申请号：US16137493

申请日：2018-09-20

Applicant: FUJIFILM CORPORATION

Inventor： Hiroki TANISAKA ,  Kyoko SENGA ,  Shuhei OSAKA

IPC: A61K31/565 ,  A61K9/08 ,  A61K47/10 ,  A61K47/44 ,  A61K9/00

Abstract: Provided is a pharmaceutical composition which contains fulvestrant in an amount of equal to or greater than 8% by mass with respect to the entire mass of the pharmaceutical composition, an aqueous solvent satisfying (1) to (4), and a pharmaceutically acceptable nonaqueous carrier satisfying (A) and (B). (1) Ethanol is contained in an amount of equal to or greater than 8% by mass with respect to the entire mass of the pharmaceutical composition. (2) At least one kind of polyhydric alcohol selected from propylene glycol or 1,3-butylene glycol is contained in an amount of equal to or greater than 3% by mass with respect to the entire mass of the pharmaceutical composition. (3) A content of benzyl alcohol is less than 5% by mass with respect to the entire mass of the pharmaceutical composition. (4) A content of the aqueous solvent is 15% to 50% by mass with respect to the entire mass of the pharmaceutical composition. (A) A content of benzyl benzoate is less than 1% by mass with respect to the entire mass of the pharmaceutical composition. (B) A content of the nonaqueous carrier is 40% to 75% by mass with respect to the entire mass of the pharmaceutical composition.

公开(公告)号：US20160168139A1

公开(公告)日：2016-06-16

申请号：US15052252

申请日：2016-02-24

Applicant: FUJIFILM Corporation

Inventor： Yohei KUBO ,  Makoto ANDO ,  Hidehiko TANAKA ,  Shuhei OSAKA ,  Takuya MATSUMOTO ,  Hiyoku NAKATA ,  Daisuke TERADA ,  Tatsuya NITABARU

IPC: C07D413/14 ,  C07D409/14 ,  C07D498/08 ,  C07D491/048 ,  C07D411/14 ,  C07D498/04 ,  C07D405/14 ,  C07D491/052 ,  C07D411/04 ,  C07D409/04 ,  C07D405/04

CPC classification number: C07D413/14 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/55 ,  A61K31/553 ,  C07D401/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D411/04 ,  C07D411/14 ,  C07D417/14 ,  C07D491/048 ,  C07D491/052 ,  C07D491/056 ,  C07D491/107 ,  C07D498/04 ,  C07D498/08

Abstract: There is provided a morpholine derivative represented by General Formula [1A] or a salt thereof. (In the formula, a ring A represents a ring represented by General Formula [I]; * represents a bonding position; Z2 represents CH or the like; Z1 represents CR6 or the like; R6 represents a hydrogen atom or the like; X1 represents CHR7 or the like; R7 represents a hydrogen atom or the like; X2 represents CH2 or the like; R1 and R2 are the same as or different from each other, and each of R1 and R2 represents a hydrogen atom or the like; R3, R4, and R5 are the same as or different from each other, and each of R3, R4, and R5 represents a hydrogen atom, NRaRb, or the like; and each of Ra and Rb represents a hydrogen atom, a C1-8 alkyl group which may have a substituent, or the like.)

Abstract translation: 提供由通式[1A]表示的吗啉衍生物或其盐。 （式中，环A表示通式[I]表示的环; *表示键合位置，Z 2表示CH等，Z1表示CR 6等，R 6表示氢原子等; X 1表示 CHR 7等; R 7表示氢原子等; X 2表示CH 2等; R 1和R 2相同或不同，R 1和R 2各自表示氢原子等; R 3， R 4和R 5彼此相同或不同，R 3，R 4和R 5各自表示氢原子，NR a R b等; R a和R b分别表示氢原子，C 1-8烷基 可以具有取代基的基团等）